Business Case

Developed global view of heath systems’ capacity to administer a novel Alzheimer’s drug to inform investment decisions at a large pharmaceutical company

A large, multi-national pharmaceutical company sought to launch their Alzheimer’s product in Italy, and needed to understand the value a subcutaneous administration would provide for the health system in reduced HCP workload and resulting increased patient throughput and capacity. Before proceeding with market entry planning, our client asked LSC to understand this impact. LSC undertook a detailed analysis, evaluating the capabilities and capacity of treatment center, resulting in a set of preliminary, center-directed value arguments. Ultimately, our client was able to incorporate center-specific activation plans to ensure maximal uptake of the therapy at launch.